Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Filters applied: . Clear all
Page 1
Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial.
Burggraaf-van Delft JLI, van Rein N, Bemelmans RHH, van den Berg JK, Bruggeman CY, Cloos-van Balen M, Coppens M, Eefting M, Ende-Verhaar Y, van Es N, van Guldener C, de Jong WK, Kleijwegt F, Koster T, Kroon C, Kuipers S, Leentjens J, Luijten D, Mairuhu ATA, Meijer K, van de Ree MA, Roos R, Schrover I, Swart-Heikens J, van der Velden AWG, van den Akker-van Marle EM, le Cessie S, Geersing GJ, Middeldorp S, Huisman MV, Klok FA, Cannegieter SC; L-TRRiP investigators. Burggraaf-van Delft JLI, et al. BMJ Open. 2024 Mar 23;14(3):e078676. doi: 10.1136/bmjopen-2023-078676. BMJ Open. 2024. PMID: 38521524 Free PMC article.
The aim of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study is to evaluate the outcomes of tailored duration of long-term anticoagulant treatment based on individualised assessment of rVTE and major bleeding risks. ...
The aim of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study is to evaluate the outcomes of tailored duration of long-term …
Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism.
de Jong CMM, Visser C, Bemelmans RHH, Boersma WG, van den Borst B, Burggraaf JLI, Cannegieter SC, Ten Cate-Hoek AJ, Croles FN, Faber HJ, Faber LM, Hellemons ME, Hessels LM, Huisman MV, Kamphuisen PW, Koster SCE, Kroft LJM, van der Lee I, Leentjens J, Meijer K, Ninaber MK, Sondermeijer BM, Stads S, Vonk Noordegraaf A, Winckers K, Kruip MJHA, Klok FA; Dutch COVID & Thrombosis Coalition investigators. de Jong CMM, et al. Among authors: faber lm. Eur Respir J. 2023 Apr 20;61(4):2300171. doi: 10.1183/13993003.00171-2023. Print 2023 Apr. Eur Respir J. 2023. PMID: 37080574 Free PMC article.
The results of this study suggest that CTEPH is not a more common long-term complication after COVID-19-associated PE than after PE in non-COVID-19 patients, and thrombus resolution did not seem to be different from non-COVID-19-associated PE https://bit.ly/3IjvWL3 The inc …
The results of this study suggest that CTEPH is not a more common long-term complication after COVID-19-associated PE than after PE i …